Serge Fratte
Overview
Explore the profile of Serge Fratte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, et al.
BMC Cancer
. 2023 Jul;
23(1):710.
PMID: 37516867
Background: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L1...
2.
Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, et al.
Front Oncol
. 2022 Mar;
12:763926.
PMID: 35340264
Background: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined...
3.
Gruner M, Denis A, Masliah C, Amil M, Metivier-Cesbron E, Luet D, et al.
Endoscopy
. 2020 Jul;
53(7):674-682.
PMID: 32698233
Background: Narrow-band imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect esophageal squamous cell carcinoma (SCC) but its specificity, which appears higher than that of Lugol chromoendoscopy in expert...
4.
Delattre J, Cohen R, Henriques J, Falcoz A, Emile J, Fratte S, et al.
J Clin Oncol
. 2020 Mar;
38(15):1702-1710.
PMID: 32167864
Patients And Methods: A post hoc analysis of all pathologic reports from patients with stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier: NCT00958737) investigating the...
5.
Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al.
J Clin Oncol
. 2018 Apr;
36(15):1469-1477.
PMID: 29620995
Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods...
6.
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, et al.
Ann Oncol
. 2015 Mar;
26(4):822-825.
PMID: 25814651
No abstract available.
7.
Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, et al.
Cancer Epidemiol Biomarkers Prev
. 2015 Jan;
24(3):603-12.
PMID: 25583947
Background: Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic colorectal cancer (mCRC) are lacking. Angiopoietin-2 (Ang-2) is proposed as a potential biomarker in several cancers. We therefore decided to...
8.
Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, et al.
BMC Gastroenterol
. 2014 Aug;
14:143.
PMID: 25117717
Background: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and...
9.
Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, et al.
Cancer Chemother Pharmacol
. 2014 May;
74(1):141-50.
PMID: 24824852
Background: Perioperative chemotherapy improves the overall survival of resectable gastroesophageal adenocarcinoma (GEA) patients. However, more than 40 % of the patients are not healthy enough to complete their post-operative chemotherapy,...
10.
Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, et al.
BMC Cancer
. 2013 Dec;
13:611.
PMID: 24373251
Background: Optimization of chemotherapy effectiveness in metastatic colorectal cancers (mCRC) is a major endpoint to enhance the possibility of curative intent surgery. FOLFIRI3 has shown promising results as second-line chemotherapy...